<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740181</url>
  </required_header>
  <id_info>
    <org_study_id>BrUOG-AML-217</org_study_id>
    <secondary_id>MGI Pharma#DAC 022/2007</secondary_id>
    <nct_id>NCT00740181</nct_id>
  </id_info>
  <brief_title>Decitabine, Cytarabine, GCSF for Refractory AML/MDS</brief_title>
  <official_title>A Phase II Study With Decitabine, Low Dose Cytarabine and G-CSF in High-risk Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia or Acute Myeloid Leukemia in Patients With Significant Co-morbidities.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Memorial Hospital of Rhode Island</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roger Williams Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the activity of decitabine, low dose cytarabine (ARA-C) and G-CSF
      for patients with myelodysplasia and leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine the feasibility and toxicity of
      decitabine, ARA-C and G-CSF for patients with myelodysplasia, refractory acute leukemia and
      poor performance status acute leukemia.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>within 30 days of last treatment</time_frame>
    <description>Complete Response/Complete Remission:
Complete remission (CR) is defined as the presence of all of the following:
Peripheral blood - No leukemic blasts present.
No extramedullary findings of leukemia or disappearance of such (i.e. CNS or soft tissue involvement)
Bone marrow
No Auer rods
Less than 5% blast cells.
CBC and bone marrow criteria must be met within one week of each other.
Hemoglobin 9g/dl or greater
Neutrophil count &gt;1000 and platelet count &gt;100,000.
RBC Transfusion free for 2 weeks.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Myelodysplasia</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine 20 mg/m2 IV over 1 hr days 1-5 Cytarabine 20 mg/m2 subcut days 1-5 G-CSF 5mcg/kg subcut days 1-5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients must have histological confirmation of disease prior to enrollment on
             study.

          -  Patients with de novo AML who are not eligible for induction chemotherapy are
             eligible. Patients with refractory, relapsed AML are eligible.

          -  Patients with AML evolving from prior MDS or secondary to prior chemotherapy are
             eligible provided they are not eligible for standard induction chemotherapy.

          -  Patients with MDS and with blasts &gt; 10% (RAEB-II) are eligible.

          -  Patients with extramedullary relapse only (i.e., leukemia cutis or other
             extramedullary site) are eligible as long as disease can be monitored.

          -  Patients who have relapsed after standard autologous and/or allogeneic bone marrow
             transplant are eligible as long as they meet all other eligibility criteria.

          -  Patients must not have had any chemotherapy, except hydrea, or radiation for at least
             4 weeks prior.

          -  Patients must be &gt; 18 years of age.

          -  Patients with an active second malignancy other than non-melanoma skin cancers are not
             eligible.

          -  Patients must have an expected life expectancy of &gt; 12 weeks at the time of
             enrollment.

          -  Patients with visceral, blood stream or nervous system opportunistic infection are
             eligible if the infection has been appropriately treated and controlled. Patients with
             fungal lung infections must have had treatment for at least one month and have proof
             of regression prior to enrollment. Patients may be on antimicrobials at the time of
             therapy.

          -  Initial required laboratory values:

               -  Total Bilirubin &lt; 2 X upper limit of normal.

               -  AST &amp; ALT &lt; 3 X upper limit of normal (if elevated liver enzymes thought likely
                  due to Leukemic infiltrate discuss with the Principal Investigator and the BrUOG
                  Central Office).

               -  Creatinine &lt; 2 mg/dl.

               -  &lt; 15,000 K/uI blast countâ€”Hydroxyurea can be used to decrease count if more than
                  15,000 K/ul.

          -  Patients must have an ECOG performance status of 0-2.

          -  Patients must receive and sign a full informed consent.

          -  Patients should not have co-existing medical illnesses which would limit survival &lt; 12
             weeks.

          -  No known history of HIV.

          -  The safety of decitabine in human pregnancy is unknown. Based on animal studies,
             decitabine may cause fetal harm when administered to a pregnant woman. Therefore, it
             is important that you do not become pregnant or father a child while receiving study
             medication and for 2 months afterwards because the drugs in this study may affect an
             unborn baby.

          -  If you are a woman capable of becoming pregnant (not surgically sterile or
             post-menopausal), you must have a negative pregnancy test before beginning treatment.

        If you do become pregnant, suspect you are pregnant, or if your partner becomes pregnant
        while you are on this study, you must notify your study doctor immediately. If you become
        pregnant, you will be taken off this study.

        In addition, you must not breast feed at any time you are on this study since any drugs you
        are taking may also affect the child.

        If you are capable of giving birth to or fathering a child, you must agree to use a form of
        birth control (examples of effective birth control are: a condom or a diaphragm with
        spermicidal jelly; oral, injectable, or implanted birth control; or abstinence) that is
        medically acceptable to your study doctor while taking part in this research study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Butera</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lifespan Hospitals</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2008</study_first_submitted>
  <study_first_submitted_qc>August 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2008</study_first_posted>
  <results_first_submitted>May 14, 2013</results_first_submitted>
  <results_first_submitted_qc>May 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2013</results_first_posted>
  <last_update_submitted>July 27, 2014</last_update_submitted>
  <last_update_submitted_qc>July 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>James Butera</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>myelodysplasia</keyword>
  <keyword>refractory leukemia</keyword>
  <keyword>acute leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>9 patients were enrolled beginning April 2009 to February 2010</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Chemotherapy</title>
          <description>Decitabine 20 mg/m2 IV over 1 hr days 1-5 Cytarabine 20 mg/m2 subcut days 1-5 G-CSF 5mcg/kg subcut days 1-5</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chemotherapy</title>
          <description>Decitabine 20 mg/m2 IV over 1 hr days 1-5 Cytarabine 20 mg/m2 subcut days 1-5 G-CSF 5mcg/kg subcut days 1-5</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Complete Response/Complete Remission:
Complete remission (CR) is defined as the presence of all of the following:
Peripheral blood - No leukemic blasts present.
No extramedullary findings of leukemia or disappearance of such (i.e. CNS or soft tissue involvement)
Bone marrow
No Auer rods
Less than 5% blast cells.
CBC and bone marrow criteria must be met within one week of each other.
Hemoglobin 9g/dl or greater
Neutrophil count &gt;1000 and platelet count &gt;100,000.
RBC Transfusion free for 2 weeks.</description>
        <time_frame>within 30 days of last treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy</title>
            <description>Decitabine 20 mg/m2 IV over 1 hr days 1-5 Cytarabine 20 mg/m2 subcut days 1-5 G-CSF 5mcg/kg subcut days 1-5</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Complete Response/Complete Remission:
Complete remission (CR) is defined as the presence of all of the following:
Peripheral blood - No leukemic blasts present.
No extramedullary findings of leukemia or disappearance of such (i.e. CNS or soft tissue involvement)
Bone marrow
No Auer rods
Less than 5% blast cells.
CBC and bone marrow criteria must be met within one week of each other.
Hemoglobin 9g/dl or greater
Neutrophil count &gt;1000 and platelet count &gt;100,000.
RBC Transfusion free for 2 weeks.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Pre-study and prior to each cycle of treatment (on average for 2 cycles, approximately 8-10 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chemotherapy</title>
          <description>Decitabine 20 mg/m2 IV over 1 hr days 1-5 Cytarabine 20 mg/m2 subcut days 1-5 G-CSF 5mcg/kg subcut days 1-5</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>death within 30 days treatment- disease related</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>dyspnea/penumonitis and bilateral infiltrates , death within 30 days of treatment</sub_title>
                <description>not related to txt</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>hemmorrhage-brain, pain-neuro(H/A), weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>acute respiratory failure- death not related, neutropenic fever - not related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>infection, neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>fever, infection/pulmonary/upper respiratory (pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>PLT, hemorrhage bladder &amp; CHF/L ventricular systolic dysfunction, infection-pulmonary</sub_title>
                <description>also: constipation(3), urinary retention(2)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>thrombocytopenia, mucositis, dehydration, dysphagia, syncope, anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>hypoxic respiratory failure and septic shock- possibly related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>thrombocytopenia, hypoxia, pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>syncopal episodes and anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James Butera</name_or_title>
      <organization>Brown Univeristy Oncology Research Group</organization>
      <phone>401-863-3000</phone>
      <email>Kayla_Rosati@brown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

